These answers are from people with first hand experience being treated with the Checkpoint Inhibitor Immunotherapies (like nivolumab, pembrolizumab, atezolizumab and durvalumab). Answers come from people with various types of cancer.
The questions below need answers. If you can contribute, please feel free to send us an answer. You can also ask your own question.
Consider joining Navio's quality of life study to learn how your experience compares with other people taking nivolumab.See Study Details